These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23256474)

  • 1. Fit-for-purpose bioanalytical cross-validation for LC-MS/MS assays in clinical studies.
    Xu X; Ji QC; Jemal M; Gleason C; Shen JX; Stouffer B; Arnold ME
    Bioanalysis; 2013 Jan; 5(1):83-90. PubMed ID: 23256474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects.
    Van Eeckhaut A; Lanckmans K; Sarre S; Smolders I; Michotte Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(23):2198-207. PubMed ID: 19179125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsule review on bioanalytical method transfer: opportunities and challenges for chromatographic methods.
    Lin ZJ; Li W; Weng N
    Bioanalysis; 2011 Jan; 3(1):57-66. PubMed ID: 21175367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays.
    Aubry AF
    Bioanalysis; 2011 Aug; 3(16):1819-25. PubMed ID: 21877891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins.
    Duggan JX; Vazvaei F; Jenkins R
    Bioanalysis; 2015; 7(11):1389-95. PubMed ID: 26110712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.
    van Nuland M; Rosing H; Schellens JHM; Beijnen JH
    Biomed Chromatogr; 2020 Jan; 34(1):e4623. PubMed ID: 31215049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Historical perspective on the development and evolution of bioanalytical guidance and technology.
    Shah VP; Bansal S
    Bioanalysis; 2011 Apr; 3(8):823-7. PubMed ID: 21510754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective data analysis and proposal of a practical acceptance criterion for inter-laboratory cross-validation of bioanalytical methods using liquid chromatography/tandem mass spectrometry.
    Yoneyama T; Kudo T; Jinno F; Schmidt ER; Kondo T
    AAPS J; 2014 Nov; 16(6):1226-36. PubMed ID: 25124547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerating high quality bioanalytical LC/MS/MS assays using fused-core columns.
    Badman ER; Beardsley RL; Liang Z; Bansal S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(25):2307-13. PubMed ID: 20674519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a quantitative assay based on tandem mass spectrometry.
    Honour JW
    Ann Clin Biochem; 2011 Mar; 48(Pt 2):97-111. PubMed ID: 21303874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic evaluation of the root cause of non-linearity in liquid chromatography/tandem mass spectrometry bioanalytical assays and strategy to predict and extend the linear standard curve range.
    Yuan L; Zhang D; Jemal M; Aubry AF
    Rapid Commun Mass Spectrom; 2012 Jun; 26(12):1465-74. PubMed ID: 22592990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in implementing clinical liquid chromatography-tandem mass spectrometry methods--the light at the end of the tunnel.
    Clarke W; Rhea JM; Molinaro R
    J Mass Spectrom; 2013 Jul; 48(7):755-67. PubMed ID: 23832931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An automation-assisted generic approach for biological sample preparation and LC-MS/MS method validation.
    Zhang J; Wei S; Ayres DW; Smith HT; Tse FL
    Bioanalysis; 2011 Sep; 3(17):1975-86. PubMed ID: 21899506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating regulatory-compliant wide dynamic range bioanalytical assays using chip-based nanoelectrospray tandem mass spectrometry.
    Wickremsinhe ER; Ackermann BL; Chaudhary AK
    Rapid Commun Mass Spectrom; 2005; 19(1):47-56. PubMed ID: 15570573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery.
    Sleczka BG; D'Arienzo CJ; Tymiak AA; Olah TV
    Bioanalysis; 2012 Jan; 4(1):29-40. PubMed ID: 22191592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis of antipsychotic drugs in human matrices using LC-MS(/MS).
    Saar E; Beyer J; Gerostamoulos D; Drummer OH
    Drug Test Anal; 2012 Jun; 4(6):376-94. PubMed ID: 22573584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the heterogeneous IT landscape of bioanalytical laboratories to increase efficiency of regulatory reporting and data analysis.
    Bittner N
    Bioanalysis; 2011 Jul; 3(13):1429-32. PubMed ID: 21728766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study.
    Elsinghorst PW; Kinzig M; Rodamer M; Holzgrabe U; Sörgel F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1686-96. PubMed ID: 21536505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. System suitability in bioanalytical LC/MS/MS.
    Briscoe CJ; Stiles MR; Hage DS
    J Pharm Biomed Anal; 2007 Jun; 44(2):484-91. PubMed ID: 17433601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.